Alkermes To Spin Out Oncology Business, Says Inflation Reduction Act Boosts Its Value

Company Raised CNS Product Revenue Guidance

After a year of strong commercial performance for Lybalvi and with IL-2 drug nemvaleukin in registration-enabling studies, Alkermes is ready to separate its neuroscience and oncology businesses. 

chain with arrows splits into two
The oncology business will split off from Alkermes in H2 2023 • Source: Shutterstock

Alkermes plc has been thinking about the best way to derive the most value from its oncology assets for some time and CEO Richard Pops said the timing is finally right for what the firm believes to be the top strategy going forward – spinning out the interleukin-2 (IL-2) drug nemvaleukin alfa and two additional cytokine therapeutics into a separate oncology company.

Pops also noted that the value of the spin-out will be enhanced by provisions in the Inflation Reduction Act (IRA), signed into law in the US this year, that Alkermes believes makes

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By 

The German biotech has been forced into insolvency and NASDAQ suspension.

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By 

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

More from Business

Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss

 

Plus deals involving Minghui/Qilu, LENZ/Lotus, Amicus/Dimerix, Sanofi/Dr. Reddy’s, Henlius/Lotus, Apnimed/Desitin, Formosa/Saval, DAAN/GC Cell, VelaVigo/Ollin and Sol-Gel/Mayne.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By 

The German biotech has been forced into insolvency and NASDAQ suspension.

Stock Watch: Bayer, Bavarian Nordic Bring European Cheer To Pharma

 
• By 

Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.